UnicoCell Biomed Co (TPE:6794) Total Equity: NT$865.44 Mil (As of Dec. 2025)


TPE:6794 UnicoCell Biomed Co Ltd TPE:6794
83 GF Score
Price NT$85.20
GF Value NT$101.57
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is UnicoCell Biomed Co Total Equity?

UnicoCell Biomed Co TPE:6794 +4.67% 83 Total Equity is NT$865.44 Mil as of Dec. 2025. GuruFocus rates TPE:6794 with a GF Score™ of 83/100 and a GF Value™ of NT$101.57 (Modestly Undervalued). The stock has 4 warning signs investors should review.

UnicoCell Biomed Co's total equity for the quarter that ended in Dec. 2025 was NT$865.44 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

UnicoCell Biomed Co Total Equity Historical Data

* Premium members only.

The historical data trend for UnicoCell Biomed Co's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

UnicoCell Biomed Co Total Equity Chart

UnicoCell Biomed Co Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial Premium Member Only 263.01 333.85 596.44 684.61 865.44

UnicoCell Biomed Co Quarterly Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 684.61 779.69 750.51 726.16 865.44
TPE:6794
83GF Score
UnicoCell Biomed Co Ltd TPE:6794
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

UnicoCell Biomed Co Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

UnicoCell Biomed Co's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=946.012-80.577
=865.44

UnicoCell Biomed Co's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=946.012-80.577
=865.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of NT$865.44 Mil mean?
UnicoCell Biomed Co (TPE:6794) has a Total Equity of NT$865.44 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for UnicoCell Biomed Co and its competitors.
Is UnicoCell Biomed Co's Total Equity too high?
UnicoCell Biomed Co's current Total Equity is NT$865.44 Mil. Overall, UnicoCell Biomed Co has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does UnicoCell Biomed Co's Total Equity compare to VRTX and REGN?
UnicoCell Biomed Co's Total Equity of NT$865.44 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for UnicoCell Biomed Co and its competitors. UnicoCell Biomed Co's current Total Equity is NT$865.44 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UnicoCell Biomed Co stock overvalued right now?
Based on GuruFocus' analysis, UnicoCell Biomed Co (TPE:6794) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$101.57, compared to a current price of NT$85.20 — trading 16.1% below its estimated fair value. The current Total Equity is NT$865.44 Mil. UnicoCell Biomed Co's overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For UnicoCell Biomed Co (TPE:6794), the current Total Equity is NT$865.44 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is UnicoCell Biomed Co (TPE:6794) Overvalued in 2026?

Based on GuruFocus' analysis, UnicoCell Biomed Co stock appears to be undervalued. The current stock price of NT$85.20 is trading 16.1% below its estimated GF Value™ of NT$101.57. GuruFocus considers UnicoCell Biomed Co to be Modestly Undervalued.

Key valuation signals for TPE:6794:

  • Total Equity: NT$865.44 Mil
  • GF Value™: NT$101.57 vs. price of NT$85.20 (16.1% below fair value)
  • GF Score™: 83/100 with 4 warning signs

No single metric tells the full story. See the TPE:6794 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

UnicoCell Biomed Co Business Description

Address Minquan East Road, 5th Floor, No. 13-20, Section 6, Neihu District, Taipei, TWN, 11494
UnicoCell Biomed Co Ltd is engaged in new drug R&D and human tissue-derived stem cell inspection and testing, extraction, storage, and technology R&D. It focuses on researching and developing stem cells and its derived technology for medical applications, with the goal of advancing human health and improving quality of life. The company's products include Allogeneic Adipose Stem Cell Bank, Autologous Stem Cell Therapy, Conditioned Medium, Mass Production and CDMO, Cryogenic Vial (Class 2 Medical Device), and Testing services. It operates in single segment. Geographically, its operations are spread across Taiwan, Japan and Others with Taiwan generating the majority of the revenue.
83GF Score

Get the complete analysis for TPE:6794

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$85.20
Price
NT$101.57
GF Value